Vasculitis
With numerous national and international meetings taking place throughout the year, choosing which conferences to attend can be difficult. While scientific programs remain a major draw, opportunities for networking, collaboration, career development and presenting research are often just as valuable. To help identify the meetings making the biggest impact across rheumatology, we asked members of the touchIMMUNOLOGY community to share the conferences they're prioritizing this year and what makes them worth attending.
Recent regulatory developments highlight a steady acceleration in therapeutic progress across rare immunological diseases, spanning autoimmune, autoinflammatory and primary immunodeficiency disorders. While individually rare, these conditions collectively represent a growing area of focus, with advances increasingly driven by targeted modulation of specific immune pathways. A series of recent approvals and designations across major regulatory regions underscores both the clinical need and the expanding therapeutic toolkit in this space.
Upadacitinib, an oral JAK inhibitor, has been approved in the UK, EU, and USA for the treatment of giant cell arteritis (GCA), supported by results from the 52-week phase 3 SELECT-GCA trial. The study was extended for another 52 weeks in a re-randomized, double-blind phase to evaluate long-term efficacy and safety. In an interview with touchIMMUNOLOGY, Prof. Wolfgang Schmidt (Charité University Medicine, Berlin) discusses the trial’s design, 2-year outcomes, and the potential role of upadacitinib in the evolving treatment landscape for GCA.
This interview with Dr Brian Jaros, part of our Future Leaders series, highlights his journey into vasculitis, his passion for medical education, and his outlook on the evolving landscape of rheumatology. He shares insights on mentorship, research, and the importance of leading with enthusiasm to inspire the next generation of clinicians.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The European Commission has approved upadacitinib for treating giant cell arteritis (GCA) in adults. This marks the first oral JAK inhibitor approved for GCA in the EU. Backed by the findings from the phase III SELECT-GCA trial, upadacitinib offers a new option for managing this chronic inflammatory disease in adults.
In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.
This corrects the article: “Gheriani GA, Tuetken R and Lenert P. Lane–Hamilton Syndrome: A Vasculitis Mimic Presenting with Diffuse Alveolar Haemorrhage and Positive ANCA Testing. touchREVIEWS in RMD. 2024;3(1):37–42” The patient consent statement was added incorrectly due to an editorial ...
Diffuse alveolar haemorrhage (DAH) is associated with high morbidity and mortality. The causes of DAH are diverse, and include rheumatologic conditions such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Systemic lupus erythematosus (SLE) and Goodpasture’s syndrome (Table 1). Rheumatologists ...
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitä...
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr ...
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, ...
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a spectrum of disorders primarily affecting the small blood vessels in various organs. It often affects the kidneys, causing rapidly progressive renal failure due to necrotizing crescentic glomerulonephritis. Another major cause of ...
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell ...
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis ...
Giant cell arteritis (GCA) is an inflammation of the arteries which causes multiple symptoms including head pain and tenderness and can result in vision loss. touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
